Dr Kolberg speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about the results from the phase III LILAC study, looking at ABP 980 with trastuzumab on pathologic complete response in women with HER2 early breast cancer.

He states that central evaluations support clinical equivalence of ABP 980 with trastuzumab and that the study demonstrates the feasibility of including central laboratory review of pathologic complete response rates in a large multi-centre, multinational study.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.